Prosecution Insights
Last updated: April 19, 2026
Application No. 17/945,898

Animal Contraceptive

Non-Final OA §101§DP
Filed
Sep 15, 2022
Examiner
CONIGLIO, AUDREA JUNE BUCKLEY
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Corona Feed Additives L L C
OA Round
3 (Non-Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
3y 3m
To Grant
75%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allow Rate
442 granted / 832 resolved
-6.9% vs TC avg
Strong +22% interview lift
Without
With
+21.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
50 currently pending
Career history
882
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
50.5%
+10.5% vs TC avg
§102
8.9%
-31.1% vs TC avg
§112
24.1%
-15.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 832 resolved cases

Office Action

§101 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/10/2026 has been entered. Status of the Claims Claim 1 has been amended. Claims 8-20 previously were withdrawn. Claims filed 1/14/2026 are the latest filed claims in the file wrapper, although it is noted that the document code is incorrect and does not separate claims and remarks; these amendments are entered upon filing of the RCE dated 2/10/2026. Claims 1-7 remain pending and under examination. Withdrawn Rejections The rejection of claims 1-7 under 35 U.S.C. 103 as being unpatentable over Randel in view of Swensen and Pan is withdrawn. Response to Arguments Applicant’s arguments filed 1/14/2026 (hereafter, Remarks) have been fully considered, entered upon entry with the RCE filed 2/10/2026, and are addressed as follows. Regarding the previously issued rejection of claims 1-7 under 35 U.S.C. 103 over Randel in view of Swensen and Pan, Applicant argues that the combination of references does not teach the newly narrowed range of free gossypol and therefore does not teach all claimed elements. Applicant’s calculations detailed at page 7 of Remarks are consistent with the examiner’s calculations and are accepted as reasonable and correct. Accordingly, Applicant’s argument that Randel does not teach the newly claimed feature is persuasive, as is the argument that none of the secondary references cure this deficiency. Regarding the double patenting rejections, Applicant states that Applicant will address this rejection under certain conditions. Applicant’s reply is considered non-responsive, and the rejection is maintained. As to Applicant’s assertion of “no waiver” and associated commentary on page 9 of Remarks, Applicant's arguments do not comply with 37 CFR 1.111(c) because they do not clearly point out the patentable novelty which he or she thinks the claims present in view of the state of the art disclosed by the references cited or the objections made. Further, they do not show how the amendments avoid such references or objections. Statutory Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 1-7 provisionally are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-7 of copending Application No. 17/722,120 (reference application). This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. The claims are verbatim except that the instant claims recite an intended use “for a rodent”, and the copending claims recite an intended use “for a pig”. Nevertheless, the composition claimed and its structural components are the same, and an intended use does not differentiate one from another. The compositions claimed are therefore the same invention drawn to an identical composition comprising identical components. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AUDREA B CONIGLIO whose telephone number is (571)270-1336. The examiner can normally be reached Monday - Thursday 7:00 a.m. - 5:30 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 5712720616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AUDREA B CONIGLIO/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Sep 15, 2022
Application Filed
Jul 22, 2025
Non-Final Rejection — §101, §DP
Oct 16, 2025
Response Filed
Nov 10, 2025
Final Rejection — §101, §DP
Jan 08, 2026
Response after Non-Final Action
Feb 10, 2026
Request for Continued Examination
Feb 12, 2026
Response after Non-Final Action
Feb 20, 2026
Non-Final Rejection — §101, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599137
Composition for the Drying of Tillandsia sp
2y 5m to grant Granted Apr 14, 2026
Patent 12599699
CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION
2y 5m to grant Granted Apr 14, 2026
Patent 12594231
EMULSIFIED COMPOSITION AND COSMETIC MATERIAL
2y 5m to grant Granted Apr 07, 2026
Patent 12589062
POWDERY SOLID COSMETIC PREPARATION
2y 5m to grant Granted Mar 31, 2026
Patent 12582120
COMPOSITIONS WITH FATTY ACIDS AND OPTIONAL CATIONIC COMPOUNDS AND METHODS OF USE
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
75%
With Interview (+21.6%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 832 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month